A Randomized, Double-blind, Parallel Group, Proof of Concept Study of YM178 in Comparison With Placebo and Tolterodine in Patients With Symptomatic Overactive Bladder

Trial Profile

A Randomized, Double-blind, Parallel Group, Proof of Concept Study of YM178 in Comparison With Placebo and Tolterodine in Patients With Symptomatic Overactive Bladder

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Mirabegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BLOSSOM
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 28 May 2012 integrated information from CT.gov; patient number = 262 according to ct.gov (actual or planned?) left no. from results doc unchanged. tool won't let me rearrange groups...
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top